Co-Authors
This is a "connection" page, showing publications co-authored by SANAM LOGHAVI and MICHAEL ANDREEFF.
Connection Strength
1.540
-
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 May 17; 13(1):80.
Score: 0.224
-
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023 04 24; 13(1):57.
Score: 0.224
-
TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma. 2024 Oct; 65(10):1511-1515.
Score: 0.060
-
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.
Score: 0.057
-
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
Score: 0.057
-
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.
Score: 0.056
-
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
Score: 0.052
-
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77.
Score: 0.052
-
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 May; 28(5):1097.
Score: 0.052
-
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med. 2022 03; 28(3):557-567.
Score: 0.052
-
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10.
Score: 0.051
-
Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.
Score: 0.050
-
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771.
Score: 0.049
-
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
Score: 0.049
-
Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.
Score: 0.049
-
Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.
Score: 0.048
-
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.
Score: 0.047
-
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.
Score: 0.047
-
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.
Score: 0.047
-
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
Score: 0.047
-
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.
Score: 0.045
-
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.
Score: 0.043
-
Early detection of transformation to BPDCN in a patient with MDS. Exp Hematol Oncol. 2018; 7:26.
Score: 0.041
-
MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
Score: 0.040